| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9253563 | Journal of Hepatology | 2005 | 7 Pages |
Abstract
The clinical benefit of lamivudine is greatest for patients without YMDD variants over 2 years of extended treatment. Additional therapies should be considered for patients with YMDD variants.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mario Rizzetto, Nicholas C. Tassopoulos, Robert D. Goldin, Rafael Esteban, Teresa Santantonio, E. Jenny Heathcote, Marco Lagget, Namrata K. Taak, Mary A. Woessner, Stephen D. Gardner,